Biomaterial Database

Carbenicillin and gentamycin in antibiotic combinations in vitro. 1969

R P Mouton, and B Holtrigter

UI	MeSH Term	Description	Entries
D007612	Kanamycin	Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.	Kanamycin A,Kanamycin Sulfate,Kantrex
D007709	Klebsiella	A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms arrange singly, in pairs, or short chains. This genus is commonly found in the intestinal tract and is an opportunistic pathogen that can give rise to bacteremia, pneumonia, urinary tract and several other types of human infection.
D010406	Penicillins	A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)	Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011511	Proteus	A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in the intestines of humans and a wide variety of animals, as well as in manure, soil, and polluted waters. Its species are pathogenic, causing urinary tract infections and are also considered secondary invaders, causing septic lesions at other sites of the body.
D011549	Pseudomonas	A genus of gram-negative, aerobic, rod-shaped bacteria widely distributed in nature. Some species are pathogenic for humans, animals, and plants.	Chryseomonas,Pseudomona,Flavimonas
D003091	Colistin	Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.	Polymyxin E,Colimycin,Colisticin,Colistin Sulfate,Coly-Mycin,Totazina,Sulfate, Colistin
D004336	Drug Antagonism	Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy.	Antagonism, Drug,Antagonisms, Drug,Drug Antagonisms
D004357	Drug Synergism	The action of a drug in promoting or enhancing the effectiveness of another drug.	Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004926	Escherichia coli	A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.	Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005839	Gentamicins	A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin

Related Publications

R P Mouton, and B Holtrigter

[Carbenicillin and gentamycin. In vitro investigations of 2 broad-spectrum antibiotics active against Pseudomonas aeruginosa].

September 1971, Ugeskrift for laeger,

R P Mouton, and B Holtrigter

[In vitro effect of fosfomycin against Pseudomonas aeruginosa compared to carbenicillin, gentamycin and polymyxin B].

January 1978, Infection,

R P Mouton, and B Holtrigter

[Combined effect of carbenicillin and gentamycin on Bacterium pyocyaneum].

July 1969, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,

R P Mouton, and B Holtrigter

In vitro activity of carbenicillin, ticarcillin, aminoglycosides and combinations against Staphylococcus aureus.

March 1979, The Journal of antimicrobial chemotherapy,

R P Mouton, and B Holtrigter

[Letter: Treatment of infections in acute leukemia with therapeutic aplasia. Efficacy of the antibiotic combinations gentamicin-carbenicillin or colistin-carbenicillin after failure of other combinations].

January 1975, La Nouvelle presse medicale,

R P Mouton, and B Holtrigter

[Gram-negative hospitalism and its treatment with gentamycin and carbenicillin].

October 1969, Anglo-German medical review. Deutsch-englische medizinische Rundschau,

R P Mouton, and B Holtrigter

[Antibiotic combinations and bacterial resistance "in vitro"].

January 1961, Pathologie et biologie,